March 18, 2010

TO:         California Vaccines for Children (VFC) Program Providers

FROM:      Robert Schechter, M.D., Acting Chief
           Center for Infectious Diseases
           Division of Communicable Disease Control, Immunization Branch

SUBJECT:   PedvaxHIB® Returns to Market

The vaccine supply of Haemophilus influenza type B (Hib)-containing vaccines in the U.S has returned to normal levels. Children are recommended to receive their full series of Hib vaccines, including any doses missed or deferred during the recent vaccine shortage.

Merck’s Hib vaccine, PedvaxHIB®, is again routinely available for providers through the VFC Program. This means that VFC providers may choose which Hib-containing vaccines they would like to use within their practices.

Current Hib-containing Vaccine Supply

The 4 Hib-containing vaccine products listed in the table below are currently available for ordering through the California VFC Program. Please note that the primary series consists of two doses for PedvaxHIB® as compared to three doses for ActHIB® or Pentacel®. Hiberix® is only a booster dose.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Trade Name</th>
<th>Manufacturer</th>
<th>Primary Series</th>
<th>Booster</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hib</td>
<td>ActHIB®</td>
<td>sanofi pasteur</td>
<td>2, 4, and 6 months</td>
<td>12-15 months</td>
</tr>
<tr>
<td>DTaP-IPV/Hib</td>
<td>Pentacel®</td>
<td>sanofi pasteur</td>
<td>2, 4 and 6 months</td>
<td>12-15 months</td>
</tr>
<tr>
<td>Hib</td>
<td>PedvaxHIB®*</td>
<td>Merck</td>
<td>2 and 4 months</td>
<td>12-15 months</td>
</tr>
<tr>
<td>Hib</td>
<td>Hiberix®</td>
<td>GSK</td>
<td>Not indicated</td>
<td>12-15 months for children who have received doses in the primary series*</td>
</tr>
</tbody>
</table>

*Hiberix® is indicated only for the booster dose. A booster dose of Hiberix® may be administered at 12 – 15 months as long as the minimum interval of 8 weeks since the previous Hib dose is met.

+Can be used for all children, but should especially be targeted for use in American Indian/Alaska Native (AI/AN) children living in AI/AN communities.
Product Interchangeability

All of the Hib-containing products are interchangeable except for Hiberix®, which is only licensed for the booster dose for any of other Hib-containing vaccines. Hiberix® comes as a lyophilized powder that must be reconstituted with sterile saline from the accompanying prefilled syringe.

Selecting Products for Your Practice

The decision on which Hib vaccine to use should be carefully discussed by clinicians and all staff involved in administering, ordering, and storing immunizations in your practice. Practices considering switching Hib-containing vaccines (especially combination vaccines) should consider how the new vaccine will be integrated with all other vaccines that the practice currently uses.

Current VFC vaccine inventory should be depleted before using new supplies to minimize vaccine wastage of federally-purchased vaccines and a potential financial liability to your practice.

Child Care Requirements

The recent special schedule which requires one dose of a Hib containing vaccine at any age for entry into childcare for children 12 months to 4.6 years will remain in effect for 2010.

QUESTIONS?

If you have any questions, please call your VFC Field Representative or the VFC Program at: 877-243-8832 (877-2GET-VFC). You can also visit our website at www.eziz.org.

cc:  CDPH Immunization Branch Field Representatives
     Local Health Officers
     Local Health Department Immunization Coordinators
     Local Health Department CHDP Program Directors
     Tanya Homman, Acting Chief, Medi-Cal Managed Care Division, DHCS
     Luis Rico., Acting Chief, Children Medical Services Branch, DHCS
     Susan McClair, M.D., Acting Chief, Medical Policy, Medi-Cal Managed Care, DHCS
     Shabbir Ahmad, D.V.M., M.S., Ph.D., Acting Chief, Maternal, Child and Adolescent
     Health Program, CDPH
     Villa Lewis, Deputy Director, Benefits and Quality Monitoring, MRMIB
     Lilia Coleman, Benefits and Quality Monitoring, MRMIB
     Jamie Yang, Benefits and Quality Monitoring, MRMIB
     Neal Kohastu, M.D., M.P.H., Medical Policy Section, Medi-Cal Benefits, Waiver
     Analysis and Rates Division, DHCS
     Steve Shih, M.D., Medical Policy Section, Medi-Cal Benefits, Waiver Analysis and
     Rates Division, DHCS
     Alan Morita, Pharm.D., Medi-Cal Pharmacy Policy Branch, DHCS
     Jill Abramson, M.D., M.P.H., Children Medical Services Branch, DHCS